About AVT
Browse Articles
Authors
Customer Services

Original article

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

Jasper Dingemanse, Paul LM van Giersbergen, Alain Patat, Per N Nilsson

Corresponding author name: Jasper Dingemanse
Corresponding author e-mail: jasper.dingemanse@actelion.com

Citation: Antiviral Therapy 2010; 15:157-163
doi: 10.3851/IMP1506

Date accepted: 24 September 2009
Date published online: 01 April 2010

Abstract

Background: We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir.

Methods: This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) alone or in combination for 9.5 days.

Results: Combination treatment resulted in slightly lower area under the concentration–time curve during the 12 h dosing interval under steady-state conditions (AUCτ,ss) values of both lopinavir and ritonavir with geometric mean ratios (GMRs; 90% confidence intervals [CIs]) of 0.86 (0.74–0.99) for lopinavir and 0.83 (0.76–0.92) for ritonavir. The maximum concentration in steady state (Cmax,ss) of lopinavir and ritonavir remained unchanged with a GMR of 0.95 and 1.01, respectively, and the 90% CIs were within the range of 0.8–1.25. The observed effects of bosentan on lopinavir and ritonavir pharmacokinetics were considered to be not clinically relevant. The pharmacokinetics of bosentan were strongly affected by coadministration. Bosentan concentration increased up to 48-fold during the first 4 days of coadministration with lopinavir/ritonavir. At steady state, the GMR for AUCτ,ss was 5.22 (3.84–7.10) and for Cmax,ss was 6.12 (4.24–8.82). The increased exposure to bosentan was reflected in an increase in adverse events attributed to bosentan, that is, mainly headache, but not in liver enzyme abnormalities.

Conclusions: Bosentan does not affect lopinavir and ritonavir exposure to a clinically relevant extent, but tolerability of bosentan should be monitored in HIV patients under antiretroviral therapy with lopinavir/ritonavir. It is anticipated that all ritonavir-boosted protease inhibitors will have a similar effect on bosentan pharmacokinetics.

<< BACK

Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.